Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial - Abarca, Katia; Iturriaga, Carolina; Urzúa, Marcela; Le Corre, Nicole; Pineda, Augusto; Fernández, Carolina; Domínguez, Angélica; González, Pablo A; Bueno, Susan M; Donato, Paulina; Espinoza, Pilar; Fuentes, Daniela; et al. (medRxiv, 2022)
Background Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac® (Sinovac Life Sciences), an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity in previous studies, preventing severe COVID-19 cases. We further investigated the safety and efficacy of two immunization schedules of CoronaVac® in a non-inferiority trial in healthy adults.Methods This is a multi-center and randomized clinical trial. Healthy adults were enrolled at eight centers in Chile. Participants were randomly assigned to two vaccination schedules, receiving two doses with either 14 (0-14) or 28 (0-28) days between each. 2302 participants were vaccinated. The primary safety and efficacy endpoints were solicited adverse events (AE) within 7 days after each dose and compared the number of cases of SARS-CoV-2 infection 14 days after the second dose between schedules, respectively.Findings The most frequent local AE was pain at the injection site, which was less frequent in participants aged ≥60 years. Other local AEs were reported in less than 5% of participants. The most frequent systemic AEs were headache, fatigue, and myalgia. The remaining AEs were minor allergic reactions and fever. Most AEs were mild and transient. There were no significant differences for local and systemic AE between schedules. No anaphylactic reactions or vaccine-related severe AEs were observed. 58 COVID-19 cases were confirmed, and all but two of them were mild. No differences were observed in protection between schedules.Interpretation CoronaVac® is safe, especially in ≥60 years-old participants. Both schedules protected against COVID-19 hospitalizations.Funding MINSAL, Chile, CPC & IMII, Chile.Evidence before this study CoronaVac® (an inactivated SARS-CoV-2 vaccine) was approved on June 1st, 2021, by the WHO for its use in humans. Sinovac Life Sciences generated this vaccine in China and conducted phase 1/2 trials. Good safety, efficacy, and immunogenicity profiles were reported. The results from this study led to the use of CoronaVac® in other countries, such as Brazil, Turkey, and Chile, with phase 3 trials being held on them.Added-value of this study This work compares the safety and efficacy of two immunization schedules with CoronaVac®, with each dose administrated two or four weeks after the first dose on healthy Chilean adults. To date, no studies showing the safety and efficacy of these two immunization schedules with CoronaVac® in healthy adults in a population other than the Chinese have been published. We show that CoronaVac® is safe and prevents hospitalization due to COVID-19 in both immunization schedules. No differences were found in the incidence of adverse events between both schedules, and no related severe adverse events were reported. These results give further insight into the immune response induced by CoronaVac® and are relevant when deciding on the immunization schedule chosen for vaccination.Implications of all the available evidence The data reported here show that using either immunization schedule with two doses of CoronaVac® protects against SARS-CoV-2. The data also indicate that CoronaVac® does not induce severe adverse events in either immunization schedule, and the adverse events registered are mild and transient, confirming the safety of this vaccine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04651790Funding StatementThe Ministry of Health, Government of Chile, supported the funding of the CoronaVac03CL Study; The Confederation of Production and Commerce (CPC), Chile, supported the funding of the CoronaVac03CL Study; The Millennium Institute on Immunology and Immunotherapy, ANID - Millennium Science Initiative Program ICN09_016 (former P09/016-F) supports SMB, KA, PAG, and AMK; The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports SMB, PAG, and AMK. SINOVAC contributed to this study with the investigational vaccine and placebo, and experimental reagents.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the sponsoring institution Ethical Committee (ID 200708006), each Institutional Ethical Committee of the other sites, and the Public Health Institute of Chile (ISP Chile, number N 24204/20). 1.Full names and affiliations: Comite Etico Cientifico Ciencias de la Salud UC, Pontificia Universidad Catolica de Chile, Santiago, Chile Comite Etico Cientifico Universidad de Los Andes, Santiago, Chile Comite Etico Cientifico Facultad de Medicina Clenica Alemana, Universidad del Desarrollo, Santiago, Chile Comite Etico Cientefico Hospital Clinico Felix Bulnes, Santiago, Chile Comite Etico Cientifico Servicio de Salud Valparaiso-San Antonio, Valparaiso, Chile Comite Etico Cientifico Servicio de Salud Metropolitano Sur Oriente, Santiago, Chile 2.Decision of all CEC was: ApprovalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analyzed and raw data (masked to protect the information of volunteers) is available upon reasonable request to the corresponding authors through email after the publication of this article. A signed data access agreement will be requested to share the data. The study protocol is also available online and annexed to this article.